ETV6 and acute lymphoblastic leukemia: The treatment of pediatric ALL is one of the greatest successes of modern medicine (Schotte et al., 2011), since certain subtypes of ALL (e.g., TEL-AML1-translocated ALL) have a favorable 5-years survival over 85% (Meijerink et al., 2009).